Atossa Therapeutics CEO Dr. Steven Quay to Participate in ARDD 2026 Panel on Clinical Trials and Regulatory Pathways for Diseases of Aging
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
| ATOSSA GNTCS (NASDAQ: ATOS) | Delayed: 2.72 +0.19 (7.51%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $2.53 | 52 Week High | $3.64 | |||
| Open | $2.49 | 52 Week Low | $0.14 | |||
| Day High | $2.77 | P/E | N/A | |||
| Day Low | $2.46 | EPS | $0.00 | |||
| Volume | 90,657 | |||||
